Clinical Trials
10 trialsNCT05627245 2026-05-13
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02732275 2026-04-28
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06508775 2025-11-26
LONGSAFE
Miltenyi Biomedicine GmbH
Phase NA Recruiting
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03646422 2022-03-31
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia Española de Dermatología
Unknown
NCT03787056 2021-07-16
ONCOPRO
Hospices Civils de Lyon
Phase NA Recruiting
NCT02017613 2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1 Completed
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed